IL4 and COVID-19: Initially, a commercially available synthetic RBD peptide of the Spike protein and the full-length RBD expressed in mammalian cells as an IL-4 fusion protein were compared using a sample set of pre-COVID-19 negative serum samples as ‘controls’ (n = 78) and convalescent samples from CMC and WCM as ‘patients’ (n = 21).